Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033774 (pruritus)
 14,546 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Topical steroid creams and ointments, applied once or twice daily, can help control psoriatic lesions and reduce itching. Intermediate-strength compounds are preferable for use in the elderly. Skin biopsy interpreted as psoriasiform dermatitis or nonspecific dermatitis, rather than psoriasis, should be considered a possible result of malignancy.
 ...
PMID:Psoriasis: how to relieve symptoms in older patients. 373 10

Alterations in the cutaneous vascular system are prominent in psoriasis and may play an important role in the pathogenesis of this disorder. We evaluated the effects of topically applied capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide), a known inhibitor of cutaneous vasodilatation, on moderate and severe psoriasis. Under a double-blind paradigm, forty-four patients with symmetrically distributed psoriatic lesions applied topical capsaicin to one side of their body and identical-appearing vehicle to the other side for 6 weeks. After 3 and 6 weeks of treatment, we performed ratings on changes in scaling and erythema, as well as overall improvement of the psoriasis. Over the course of the study, significantly greater overall improvement was observed on sides treated with capsaicin compared to sides treated with vehicle. Similarly, significantly greater reductions in scaling and erythema accompanied capsaicin application. Burning, stinging, itching, and redness of the skin were noted by nearly half of the patients on initial applications of study medication but diminished or vanished upon continued application. These results suggest that topical application of capsaicin may be a useful new approach in the treatment of psoriasis.
 ...
PMID:Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. 376 Feb 76

Ibuprofen and placebo were compared in a randomized, double-blind, cross-over study of 19 psoriatic patients receiving UV-B phototherapy to evaluate the symptomatic relief of UV-B-induced inflammation. Signs and symptoms of UV-B-induced inflammation (erythema, pruritus, skin pain, general discomfort, and nocturnal restlessness) were assessed for each treatment. An evaluation of 104 treatments disclosed that, although ibuprofen significantly reduced technician-observed erythema, it was not significantly different from placebo for the five other end points studied. Separate evaluations of higher dose UV-B treatments showed a small, but statistically significant, reduction with ibuprofen for four of the six end points evaluated. The data suggest that ibuprofen is more effective than placebo for the relief of symptoms associated with UV-B-induced inflammation after high dose UV-B phototherapy for psoriasis, but the drug has limited usefulness in the treatment of sunburn reaction from these same doses.
 ...
PMID:Ibuprofen in the treatment of UV-B-induced inflammation. 388 8

A randomized, double-blind study compared the efficacy and safety of amcinonide and betamethasone dipropionate ointments, applied twice daily for two weeks, in the treatment of patients with moderate to severe psoriasis. Thirty-four patients were enrolled; thirty patients had had psoriasis for more than one year, and in the majority of patients, it was stable or slowly exacerbating. Significant improvement from baseline was observed with both ointments at weeks 1 and 2. The two drugs showed comparable cosmetic acceptability. Adverse cutaneous symptoms experienced were burning (both groups), itching (amcinonide), and stinging (beta-methasone); no serious adverse effects were reported.
 ...
PMID:Amcinonide vs. betamethasone dipropionate ointments in the treatment of psoriasis. 389 Dec 39

Extensive lesions on 36 patients with psoriasis were treated by Tigason, I mg/kg/day plus PUVA until skin clearance. A clinical score was calculated for each body area, and erythema, scaling, thickness and pruritus of the lesions were scored from 0 to 3. Skin clearing was defined as a clinical score less than 10% of the initial score. Double-blind maintenance treatment was then started. This was Tigason at half of the maximal dose tolerated during the clearing phase of the treatment v. placebo. Relapse of the disease was defined as the occurrence of a clinical score greater than 50% of the initial score. Among the 36 patients randomized, 20 received placebo and 16 received Tigason. Relapses increased quickly in the patients on placebo, but occurred in few patients treated by Tigason with 60% remaining clear after 1 year (P less than 0.05). Surprisingly, the kinetics of disappearance of the most frequent side effect, cheilitis, was the same in the Tigason group and in the placebo group. This double-blind randomized clinical trial shows that Tigason at low doses is an efficient and well-tolerated maintenance treatment of psoriasis.
 ...
PMID:Maintenance treatment of psoriasis by Tigason: a double-blind randomized clinical trial. 390 5

H2-antagonists differ from the commonly applied antihistamines (H1-antagonists) by blocking a different spectrum of histamine-mediated pharmacologic reactions. Their effects on the skin as the target organ may be stronger, weaker, or even reverse. The main representative of this group of drugs is cimetidine. Other compounds are still in experimental stages. Some controversial effects were reported in urticaria, pruritus, atopic dermatitis, mastocytosis of the skin, and also in acne and psoriasis. With polyetiologic symptoms, as are manifested in cases of urticaria and pruritus, the efficacy of the drug may depend on the underlying disease. In acne and psoriasis, the clinical type and stage of the disease may also play a major role in the outcome of such studies. Experimental and clinical findings suggest that cimetidine has some immunomodulating effect in terms of influencing the delayed type skin hypersensitivity. The intake of cimetidine should be registered in patch testing. Application of H2-antagonists may be beneficial in diseases with reduced immune resistance (generalized mycotic infections). Serious group-specific side-effects of H2-antagonists are not yet known. Several side-effects have been reported following oral intake of cimetidine; however, their frequency seems rather low.
 ...
PMID:[H2-antagonists and possibilities for their therapeutic use in dermatology]. 613 53

Twenty-two psoriatic patients were treated orally with the antichemotactic agent, colchicine, at a dosage of 0.02 mg per kg per day for a duration of 2-4 months. Complete clearing or marked improvement were noted in 8 of the 9 patients, in whom thin papules and thin plaques were the predominant type of lesion. Much less favorable results were obtained in patients with chronic, stable, thick plaque-type disease, although decreased scaliness, erythema and infiltration and marked diminution of the pruritus were observed in almost all of the cases. A considerable improvement of the joint pains was noted in each of the 8 patients who suffered from arthralgias. Five additional patients with extensive, chronic, stable plaque-type psoriasis were given oral colchicine immediately after complete clearing of their skin lesions with Goeckerman's method or with methotrexate. Four of them continued to take colchicine for 8-9 months and during that time they remained free of significant skin disease. These findings lend support to the hypothesis that the migration of the activated psoriatic neutrophils into the skin could be an important factor in the initiation and possibly also in the perpetuation of the psoriatic lesions. Closely controlled, long-term studies conducted in large numbers of patients are warranted in order to determine the exact therapeutic role of oral colchicine in the long-term management of psoriasis.
 ...
PMID:Therapeutic trials with oral colchicine in psoriasis. 616 37

Itch was measured quantitatively as nocturnal scratch in 12 patients with psoriasis treated with 8-methoxypsoralen and UVA and in 7 treated with dithranol. Three of those treated with PUVA showed an increase in nocturnal limb movement which was mostly due to itch but partly due to restlessness. There was little change in nocturnal limb movement in patients treated with dithranol.
 ...
PMID:Itch following photochemotherapy for psoriasis. 616 4

Efficacy and tolerance of an alcoholic solution containing 0.64 mg betamethasone-dipropionate plus 20 mg salicylic acid (Diprosalic Solution) were compared with an alcoholic solution containing 0,64 mg betamethasone-dipropionate in a 3 week double blind study in 100 patients with psoriasis and other steroid-responsive dermatoses of dry nature, comprising scalp and other hairy and non-hairy areas of the body. This double blind study was followed by a 3 week open study in another 100 patients with similar diagnosis, using Diprosalic Solution only. Although the therapeutic results of the double blind study showed no significant differences between both treatment groups, distinct advantages of the drug containing salicylic acid could be clearly demonstrated, such as: 1. More rapid onset of action, 2. rapid clearing of scaling, pruritus and inflammation, 3. these advantages are in compliance with the fact that topically applied salicylic acid softens keratin, loosens cornified epithelium and desquamates the epidermis, making the underlying layers more accessible to the antiinflammatory steroid.
 ...
PMID:[Therapy of erythrosquamous dermatoses. Betamethasone dipropionate plus salicylic acid in comparison with betamethasone dipropionate solution]. 622 42

The systemic complications of therapy with lithium are well known, but toxidermia has only been recognised since 1968. The carbonate (Teralithe) is the lithium salt which is mainly responsible, leading to minor dermatoses: oedema, pruritus, alopecia, urticaria, purpura, allergic vasculitis, pretibial ulceration. Some more specific conditions have been individualised by their severity and rarity: acne form eruptions, seborrheic dermatitis, follicular keratoses and psoriasis-like dermatosis as well as true psoriasis induced or aggravated by lithium. The authors review the literature and discuss the pathogenesis of these toxidermias. The cause of some dermatoses can be explained, especially the allergic vasculitis and psoriasis lesions. The underlying mechanism of most of these conditions remains unknown, but excessive tissue concentrations of the drug probably play an important role in inducing these complications.
 ...
PMID:[Drug eruptions caused by lithium salts]. 624 39


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>